TG4001 can induce de novo immune responses against HPV16 antigens E6 and E7 in patients with advanced HPV16-positive anogenital cancers
Patients with complete objective response showed strong vaccine-induced immunoreactivity
Transgene is preparing for a potentially registrational study
Strasbourg, France, June 5, 2023, 7:30 am CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that new data will be presented today on TG4001 . These data confirm the ability of this novel investigational therapeutic cancer vaccine to induce immune responses against HPV16 antigens, that are associated with anti-tumor response. These results have been presented in a poster at the ongoing American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
…/…